Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2000

View Archived Issues

Licensing opportunity from NIH: novel treatment for inflammatory bowel disease

New chemical class with dual mechanism of action presented as promising glaucoma therapeutics

AMPA antagonist improves visual function in humans

IOP-lowering efficacy of anecortave established in preclinical models and in patients

American Cyanamid describes new inhibitors of growth factor receptor PTKs useful in cancer Rx

New rhodanine carboxylic acid derivatives useful for bone disorders

Swainsonine analogues in development at GlycoDesign as therapeutic agents

Treatment and diagnosis of tumors using urokinase inhibitors

Schering presents recent research in the area of NOS inhibitors

Selectin inhibitors under study by Otsuka

New gpIIb/IIIa inhibitor for i.v. administration with sustained pharmacodynamic effects

Quorum receives grant to develop CF therapy

Blockade of ETA receptors as promising strategy for antifibrotic therapy

DuPont expands access to liquid Sustiva in children

Fatty acid derivatives of GLP-1 suitable for once-daily treatment of diabetes

Novel platinum antitumor agent compares favorably with cisplatin in preclinical studies

Aphton begins trial of anti-G17 immunogen in metastatic gastric cancer

Vaginal mucosal vaccination against UTIs proves safe and effective in women

ImClone Systems receives notice of allowability for cancer immunotherapy

Clitoral hemodynamic changes following topical alprostadil

NIH renews HIV drug discovery funding to Panacos collaborators

AUA news: three studies confirm safety and efficacy of sublingual apomorphine for ED in CAD

Phase II trials begin for GenVec's VEGF121 gene therapy for heart disease

Pirfenidone: effects on PDGF-induced intracellular events described at EASL meeting

Neurocrine Biosciences obtains orphan drug status for glioblastoma therapy

New formulations of carteolol may reduce dosing frequency

Paxene receives marketing approval in Canada for Kaposi's sarcoma

Frovatriptan is approvable, FDA says; first European approval also in sight

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...